A5081067899- Advanced Breast Cancer Therapies
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- Colorectal Cancer Surgical Treatments
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Head and Neck Cancer Studies
- Health Systems, Economic Evaluations, Quality of Life
- Neuroendocrine Tumor Research Advances
- Colorectal and Anal Carcinomas
- Cancer Treatment and Pharmacology
- Ethics in Clinical Research
- Sarcoma Diagnosis and Treatment
- Inflammatory mediators and NSAID effects
- COVID-19 and healthcare impacts
- Pain Management and Placebo Effect
- Gastric Cancer Management and Outcomes
- BRCA gene mutations in cancer
- Cancer Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Cancer-related Molecular Pathways
- Advances in Oncology and Radiotherapy
Instituto Alexander Fleming
2020-2025
Fundación para la Investigación, Docencia y Prevención del Cáncer
2023-2025
Argentine Water and Sanitation (Argentina)
2021-2024
AC Camargo Hospital
2022
In recent years, unprecedented benefits have been observed with the development of cyclin-dependent kinase (CDK) 4 and 6 inhibitors for treatment hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. However, there is scarce evidence their value in specific populations, such as patients carrying germline pathogenic variants DNA repair-related genes.We retrospectively studied efficacy CDK 4/6 plus endocrine therapy advanced Three cohorts were...
Background/Objectives: BRAF-mutation is a poor prognostic factor in colorectal cancer (CRC). There need for real-world data low-middle-income countries regarding clinical characteristics, outcomes, and treatment strategies. This study aims to describe progression free survival (PFS) overall (OS) the first-line setting, sequences of regimens. Methods: We retrospective analyze patients from ten oncology centers Argentina, diagnosed with BRAFV600E-mutated advanced CRC between January 2014 July...
Background/Objectives: The BRAF-mutation is a poor prognostic factor in colorectal cancer (CRC). There need for real-world data low-middle-income countries regarding clinical characteristics, outcomes, and treatment strategies. This study aims to describe progression-free survival (PFS) the first- second-line setting sequences of regimens. Methods: We retrospectively analyze patients from ten oncology centers Argentina, diagnosed with BRAFV600E-mutated advanced CRC between January 2014 July...
1056 Background: HER2-low expression, defined as HER2 immunohistochemistry (IHC) score of 1+ or 2+ with negative in situ hybridization assay (FISH), accounts for 50% breast cancers. There is limited and conflicting evidence regarding the efficacy cyclin-dependent kinase (CDK) 4 6 inhibitors patients ER+ tumors. This study aimed to investigate prognostic value expression ER+/HER2-negative advanced cancer treated CDK 4/6 inhibitors. Methods: We retrospectively selected consecutive plus...
e12633 Background: Triple negative breast cancer (TNBC) has been globally associated with a high risk of carrying pathogenic or likely (P/LP) variants in germline (BC) susceptibility genes (BCSG). Immunotherapy- based Neoadjuvant (pembro-NA) treatment is the preferred approach for localized, T2 node positive TNBC. To best our knowledge, information about peridiagnostic genetic counseling (PGC), status and their impact on patients (pts) undergoing this not reported yet. Our aim was to...
Burnout (BO) syndrome is a condition that results in physical and mental distress.The current COVID-19 pandemic strongly affecting the health of general population.We aimed to assess incidence BO among medical oncologists determine factors associated with burnout levels during pandemic.Methods: A digital survey was created for this study.The Spanish-validated version Maslach Inventory incorporated define BO.Social demographic information analysed remove duplicated answers.Results: total 188...
The targeted therapy cetuximab [directed at the epidermal growth factor receptor (EGFR)] in combination with 5-fluorouracil and platinum-based chemotherapy (the EXTREME regimen) has shown substantial efficacy for patients recurrent or metastatic squamous cell carcinoma of head neck (R/M SCCHN). Thus, this scheme been established as preferred first-line option these patients. However, more recently, a new strategy combining platinum, taxanes, TPEx demonstrated similar favorable toxicity...
The COVID-19 outbreak has resulted in collision between patients infected with SARS-CoV-2 and those cancer on different fronts. Patients have been impacted by deferral, modification, even cessation of therapy. Adaptive measures to minimize hospital exposure, following the precautionary principle, proposed for care during era. We present here a consensus prioritizing recommendations across continuum sarcoma patient care.A total 125 were soft-tissue, bone, visceral care. Recommendations...
Introduction Medical research and development (R&D) is an undoubtedly relevant activity to drive innovation, improve healthcare policies bring patients treatment opportunities for common rare diseases. Equity inclusion are matters of concern in research. High-income countries’ teams more likely have impactful publications, grant funding, clinical trials than middle or low-income countries. Low budget allocations R&D existing gaps regulatory frameworks some obstacles growth....